About efpiamapps

This author has not yet filled in any details.
So far efpiamapps has created 16 blog entries.

Interview: US Personalized Medicine Coalition – Exploring Pathways Towards Patient-Centred Healthcare

July 31st, 2015 – by Alison Kilian

Adaptive pathways are among the possibilities being examined for incentivising medicine and future innovation in the United States, says Amy M. Miller, Ph.D., Executive Vice President of the Washington DC-based Personalized Medicine Coalition. But some key hurdles remain, not only from a scientific view, but also from a policy perspective. Dialogue […]

By |July 31st, 2015|News|0 Comments

MAPPs and New Benefit Risk Models: IMI2 Leads with Patient Engagement

July 10th, by Magda Chlebus

The Innovative Medicines Initiative (IMI) yesterday launched its 5th Call for proposals under the IMI 2 programme (http://www.imi.europa.eu/content/stage-1-16).  Topic 1 addresses one of the key enablers of adaptive pathways – developing methods to incorporate the input of patients into the assessments of benefits and risks of new medicines at all stages […]

By |July 13th, 2015|News|0 Comments

Event Report – MAPPs: Saving Time, Saving Lives

EFPIA General Meeting Highlights Enormous Gains Made by MAPPs and Carves a Path for the Future
17th June 2015 – by Duane Schulthess
While progress is often slow and laborious when trying to gain traction for new ideas in the ‘Brussels Bubble’, there was much to be optimistic about in the Medicine’s Adaptive Pathways to Patients (MAPPs) meeting […]

By |June 16th, 2015|News, Uncategorized|0 Comments

Interview: Get Real – Using real world data for decision-making in R&D and health technology assessment

Real world evidence holds the potential to both increase efficiency in R&D and to bridge the gap between the proof of efficacy required to pass regulatory scrutiny and the demonstration of likely effectiveness needed to satisfy health technology assessment bodies, says Professor Sarah Garner, Associate Director for Science Policy and Research at NICE

By |May 13th, 2015|News|1 Comment

Top Drug Regulator: Adaptive Licensing is a New Paradigm – for Everyone

Reinventing how medicines come to market demands new thinking from regulators, payors, patients and industry, says Professor Luca Pani, Director General of the Italian Medicines Agency.

By |April 23rd, 2015|News|0 Comments

Patients need medicines – not to die in safety: Interview with Bettina Ryll

'Patients need medicines – not to die in safety': Interview with Bettina Ryll April 7th, 2015 - by Garry Finnegan
While Europe is leading in the development of tools and methodologies in Medicine’s Adaptive Pathways (MAPPs) through the EMA live pilots and upcoming projects in IMI2, the key bottlenecks still holding back its implementation in Europe are gaining traction with the United States congress. This situation illustrates our need in Europe to move quickly and develop implementation strategies and foster political support for MAPPs whilst we still hold the drive and initiative.

By |April 6th, 2015|News|0 Comments